Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy.

Author: Kailin LI ¹ ; Jieqiong YOU ¹ ; Qian WU ¹ ; Wen MENG ² ; Qiaojun HE ¹ ; Bo YANG ¹ ; Chengliang ZHU ¹ ; Ji CAO ¹
Author Information

1. Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
2. Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Publication Type:Review
Keywords: Antitumor therapy; Cyclin-dependent kinase; MYC; Oncogenes; P53; PARP; RAS; Synthetic lethality
From: Acta Pharmaceutica Sinica B 2021;11(9):2738-2748
CountryChina
Language:English
Abstract: Synthetic lethality is a proven effective antitumor strategy that has attracted great attention. Large-scale screening has revealed many synthetic lethal genetic phenotypes, and relevant small-molecule drugs have also been implemented in clinical practice. Increasing evidence suggests that CDKs, constituting a kinase family predominantly involved in cell cycle control, are synthetic lethal factors when combined with certain oncogenes, such as